Topical Hydroquinone for Hyperpigmentation: A Narrative Review.

cosmetics hydroquinone hyperpigmentation melasma skin lightening

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 25 10 2023
accepted: 15 11 2023
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: epublish

Résumé

Topical hydroquinone (HQ) has been used for decades to treat disorders of hyperpigmentation such as melasma, post-inflammatory hyperpigmentation, and solar lentigines. Additionally, it has been used as a skin-lightening agent for cosmetic purposes. Multiple studies have shown it to be effective in treating hyperpigmentation, though it is not without side effects. Currently, HQ is not approved for over-the-counter use in the United States. Its use is also banned in other countries, including Japan, Australia, and the European Union. Hyperpigmentation disorders affect individuals worldwide. Patients with these disorders are frequently seen in medical practices. Hyperpigmentation disorders can significantly negatively impact a person's quality of life, and agents that treat hyperpigmentation can improve patient outcomes. A comprehensive literature search was performed on HQ as a treatment for skin hyperpigmentation disorders. A literature review revealed that HQ is an effective compound for treating hyperpigmentation disorders and can be combined with other therapies for enhanced results. Evidence exists to support HQ as a topical therapy for skin hyperpigmentation. HQ is not without side effects and should be prescribed by trained professionals who can educate patients on usage. HQ can be used in pharmaceutical regimens to treat hyperpigmentation disorders.

Identifiants

pubmed: 38106810
doi: 10.7759/cureus.48840
pmc: PMC10723018
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e48840

Informations de copyright

Copyright © 2023, Fabian et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Isabella M Fabian (IM)

School of Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA.

Evan S Sinnathamby (ES)

School of Medicine, Louisiana State University Health Sciences Center New Orleans, New Orleans, USA.

Chelsi J Flanagan (CJ)

School of Osteopathic Medicine, University of the Incarnate Word School of Osteopathic Medicine, San Antonio, USA.

Anne Lindberg (A)

School of Medicine, Louisiana State University Health Sciences Center New Orleans, New Orleans, USA.

Brynne Tynes (B)

School of Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA.

Rucha A Kelkar (RA)

School of Medicine, Medical University of South Carolina, Charleston, USA.

Giustino Varrassi (G)

Pain Medicine, Paolo Procacci Foundation, Rome, ITA.

Shahab Ahmadzadeh (S)

Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA.

Sahar Shekoohi (S)

Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA.

Alan D Kaye (AD)

Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA.

Classifications MeSH